Artificial intelligence and machine learning are transforming the medical device industry. Simultaneously, companies are working to gain Food and Drug Administration approval and obtain intellectual property protection for this technology.

As these changes take place and newer guidance emerges, IP practitioners need to help clients navigate these complicated areas without jeopardizing investment into AI or machine learning-enabled technology.

Originally published in Bloomberg Law - August 5, 2024.